Formula I Tyrosine Kinase Modulators for Selective Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating tyrosine kinase signal transduction are inadequate in effectively addressing unregulated tyrosine kinase activities associated with various disorders, including cancer and inflammatory diseases, as they lack specificity and efficacy.
Innovation Solution
Development of novel compounds represented by Formula I, which inhibit tyrosine kinase activity by modulating the signaling pathways, thereby regulating cell growth and differentiation, and are used in treating disorders related to unregulated tyrosine kinase signal transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for modulating tyrosine kinase signal transduction are used, then treatment of tyrosine kinase-related disorders is attempted, but the methods lack specificity and efficacy in addressing unregulated tyrosine kinase activities
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of tyrosine kinase inhibitors through various substituents (R1-R6, X, Y, Z, a, b, c, d, e, f parameters) to optimize binding affinity and selectivity for specific tyrosine kinase isoforms, thereby improving efficacy while maintaining manageable molecular complexity
Solution Approach 2:
The patent applies local quality by designing specific functional groups and substituents at different positions of the core molecular structure to target specific regions of the tyrosine kinase binding pocket, enabling selective inhibition of particular kinase isoforms involved in different disorders
2Adaptability or versatility
If current methods are used to treat tyrosine kinase-related disorders, then broad coverage is attempted, but the methods lack specificity for different disorder types
Solution Approach 1:
The patent achieves universality by creating a core molecular structure with multiple substitutable positions that can be customized to target different tyrosine kinase isoforms involved in various disorders including cancer, inflammatory diseases, and neurodegenerative conditions, allowing one platform to address multiple disease types
Solution Approach 2:
The patent applies local quality by introducing specific substituents at defined positions (R1-R6, X, Y, Z) to modulate the inhibitor's selectivity for different tyrosine kinase isoforms, enabling tailored treatment for specific disorder types while maintaining the overall molecular framework
Data Source
AI summary
The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors. ##STR00001##